Top 5 stories on HIV, ageing and co-morbidities from CROI 2022
Top 5 stories on HIV treatment and care in Africa from CROI 2022
Generic PrEP for young, at-risk MSM in the US could be cost-saving and health-enhancing
Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?
Why did an HIV vaccine fail in the Imbokodo trial?
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
Injected PrEP: breakthrough cases could have been detected sooner
Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovirals?
Further evidence that recycling tenofovir in second-line treatment is effective
